You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 25, 2024

Details for New Drug Application (NDA): 022204


✉ Email this page to a colleague

« Back to Dashboard


NDA 022204 describes GELNIQUE, which is a drug marketed by Abbvie and Allergan and is included in two NDAs. It is available from one supplier. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the GELNIQUE profile page.

The generic ingredient in GELNIQUE is oxybutynin. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the oxybutynin profile page.
Summary for 022204
Tradename:GELNIQUE
Applicant:Abbvie
Ingredient:oxybutynin chloride
Patents:3
Formulation / Manufacturing:see details
Pharmacology for NDA: 022204
Suppliers and Packaging for NDA: 022204
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
GELNIQUE oxybutynin chloride GEL;TRANSDERMAL 022204 NDA Allergan, Inc. 0023-5861 0023-5861-11 30 PACKET in 1 CARTON (0023-5861-11) / 1 g in 1 PACKET (0023-5861-10)

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:GEL;TRANSDERMALStrength10% (100MG/PACKET)
Approval Date:Jan 27, 2009TE:RLD:Yes
Patent:⤷  Sign UpPatent Expiration:Nov 6, 2029Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE WITH A SINGLE UNIT DOSE OF 10% OXYBUTYNIN CHLORIDE GEL
Patent:⤷  Sign UpPatent Expiration:Mar 26, 2031Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN
Patent:⤷  Sign UpPatent Expiration:Nov 6, 2029Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN

Expired US Patents for NDA 022204

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie GELNIQUE oxybutynin chloride GEL;TRANSDERMAL 022204-001 Jan 27, 2009 ⤷  Sign Up ⤷  Sign Up
Abbvie GELNIQUE oxybutynin chloride GEL;TRANSDERMAL 022204-001 Jan 27, 2009 ⤷  Sign Up ⤷  Sign Up
Abbvie GELNIQUE oxybutynin chloride GEL;TRANSDERMAL 022204-001 Jan 27, 2009 ⤷  Sign Up ⤷  Sign Up
Abbvie GELNIQUE oxybutynin chloride GEL;TRANSDERMAL 022204-001 Jan 27, 2009 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.